INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $746,569 | +71.7% | 40,268 | +2.4% | 0.00% | 0.0% |
| Q2 2023 | $434,868 | -19.1% | 39,319 | -1.7% | 0.00% | 0.0% |
| Q1 2023 | $537,455 | +12.4% | 40,019 | +3.5% | 0.00% | 0.0% |
| Q4 2022 | $478,373 | +13.9% | 38,672 | +28.5% | 0.00% | 0.0% |
| Q3 2022 | $420,000 | -0.5% | 30,105 | -1.4% | 0.00% | 0.0% |
| Q2 2022 | $422,000 | -24.9% | 30,534 | -11.7% | 0.00% | 0.0% |
| Q1 2022 | $562,000 | -8.0% | 34,566 | -7.9% | 0.00% | 0.0% |
| Q4 2021 | $611,000 | +8.0% | 37,511 | -1.7% | 0.00% | 0.0% |
| Q3 2021 | $566,000 | -26.6% | 38,147 | -1.3% | 0.00% | 0.0% |
| Q2 2021 | $771,000 | -14.5% | 38,631 | -1.2% | 0.00% | 0.0% |
| Q1 2021 | $902,000 | -7.0% | 39,097 | -0.4% | 0.00% | 0.0% |
| Q4 2020 | $970,000 | -40.4% | 39,262 | 0.0% | 0.00% | -66.7% |
| Q3 2020 | $1,628,000 | -13.1% | 39,262 | +0.4% | 0.00% | 0.0% |
| Q2 2020 | $1,873,000 | -22.2% | 39,092 | +2.2% | 0.00% | -40.0% |
| Q1 2020 | $2,408,000 | -49.4% | 38,240 | -0.5% | 0.01% | -37.5% |
| Q4 2019 | $4,762,000 | +83.0% | 38,430 | -2.0% | 0.01% | +60.0% |
| Q3 2019 | $2,602,000 | -14.2% | 39,206 | +2.8% | 0.01% | -16.7% |
| Q2 2019 | $3,033,000 | -19.2% | 38,123 | +13.7% | 0.01% | -25.0% |
| Q1 2019 | $3,752,000 | +8.6% | 33,538 | -2.2% | 0.01% | 0.0% |
| Q4 2018 | $3,455,000 | -18.3% | 34,284 | +2.4% | 0.01% | 0.0% |
| Q3 2018 | $4,230,000 | +50.4% | 33,473 | -0.1% | 0.01% | +33.3% |
| Q2 2018 | $2,813,000 | +67.0% | 33,523 | +22.5% | 0.01% | +50.0% |
| Q1 2018 | $1,684,000 | +1.6% | 27,375 | -3.5% | 0.00% | +33.3% |
| Q4 2017 | $1,658,000 | -0.8% | 28,381 | -1.5% | 0.00% | -25.0% |
| Q3 2017 | $1,672,000 | -56.7% | 28,810 | -9.7% | 0.00% | -50.0% |
| Q2 2017 | $3,864,000 | +4.9% | 31,914 | -2.0% | 0.01% | +14.3% |
| Q1 2017 | $3,682,000 | -0.8% | 32,559 | -4.7% | 0.01% | -12.5% |
| Q4 2016 | $3,711,000 | -35.5% | 34,159 | -2.3% | 0.01% | -33.3% |
| Q3 2016 | $5,754,000 | +16.0% | 34,959 | +0.6% | 0.01% | +9.1% |
| Q2 2016 | $4,959,000 | +13.7% | 34,759 | +2.4% | 0.01% | +22.2% |
| Q1 2016 | $4,360,000 | -1.1% | 33,936 | +14.9% | 0.01% | -18.2% |
| Q4 2015 | $4,410,000 | -8.7% | 29,529 | +1.4% | 0.01% | -15.4% |
| Q3 2015 | $4,831,000 | -31.3% | 29,129 | 0.0% | 0.01% | -23.5% |
| Q2 2015 | $7,031,000 | +1.9% | 29,129 | +19.0% | 0.02% | +6.2% |
| Q1 2015 | $6,901,000 | +90.1% | 24,471 | +5.2% | 0.02% | +77.8% |
| Q4 2014 | $3,630,000 | -33.2% | 23,271 | +1.3% | 0.01% | -30.8% |
| Q3 2014 | $5,437,000 | +1.0% | 22,973 | +1.0% | 0.01% | -7.1% |
| Q2 2014 | $5,381,000 | +25.1% | 22,742 | +74.4% | 0.01% | +27.3% |
| Q1 2014 | $4,301,000 | +386.5% | 13,042 | +0.8% | 0.01% | +450.0% |
| Q4 2013 | $884,000 | +0.5% | 12,942 | +1.6% | 0.00% | -33.3% |
| Q3 2013 | $880,000 | +79.2% | 12,742 | +16.5% | 0.00% | +50.0% |
| Q2 2013 | $491,000 | +59.9% | 10,942 | +33.4% | 0.00% | +100.0% |
| Q1 2013 | $307,000 | – | 8,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |